Literature DB >> 16505981

[Outcome parameters in ankylosing spondylitis].

H Haibel1, M Rudwaleit, J Sieper.   

Abstract

Ankylosing spondylitis (AS) is a frequent inflammatory rheumatic disease and prototype of the Spondyloarthitides (SpA). During the last years outcome parameters have been developed to evaluate different aspects of the disease. Among these are the Bath AS Disease Activity Index (BASDAI), Bath AS Functional Index (BASFI), Bath AS Metrology Index (BASMI), numeric rating scales for general pain, night pain, patients and physicians global assessment, as well as questionnaires to evaluate quality of life as the short Form (SF)- 36, Euroquol 5 Dimensions (EQ-5D), or the AS specific the ASQuol. These outcome parameters are the basis to conduct clinical trials. The ASessements in AS (ASAS) improvement criteria were developed to evaluate the short term efficacy of Non-Steroidal Antirheumatic Drugs (NSAIDs) and adjusted for the measurement of the high efficacy of the TNF-alpha blocking agents. To examine the x-rays of sacroiliac joints (SIG), the radiological criteria as part of the modified New York criteria are mostly used. For the x-rays of the spine the Bath AS Radiology Index (BASRI) is valuable in daily practice, but the modified Stokes AS Spine Score (mSASSS) is more sensitive for clinical trials. To examine Magnetic Resonance Images (MRI) of SIG and spine also scores are currently developed. Altogether, using the new outcome parameters it was possible to demonstrate the strikingly high efficacy of theTNF-alpha blocking agents. However, it could also be shown that conventional disease modifying antirheumatic drugs (DMARDs) are not effective in the treatment of the axial forms of SpA.

Entities:  

Mesh:

Year:  2006        PMID: 16505981     DOI: 10.1007/s00393-006-0038-3

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  29 in total

Review 1.  How should treatment effect on spinal radiographic progression in patients with ankylosing spondylitis be measured?

Authors:  Désirée van der Heijde; Robert Landewé; Sjef van der Linden
Journal:  Arthritis Rheum       Date:  2005-07

2.  Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis.

Authors:  L C Doward; A Spoorenberg; S A Cook; D Whalley; P S Helliwell; L J Kay; S P McKenna; A Tennant; D van der Heijde; M A Chamberlain
Journal:  Ann Rheum Dis       Date:  2003-01       Impact factor: 19.103

3.  The Bath Ankylosing Spondylitis Patient Global Score (BAS-G).

Authors:  S D Jones; A Steiner; S L Garrett; A Calin
Journal:  Br J Rheumatol       Date:  1996-01

4.  Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria.

Authors:  S van der Linden; H A Valkenburg; A Cats
Journal:  Arthritis Rheum       Date:  1984-04

5.  Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis.

Authors:  J J Anderson; G Baron; D van der Heijde; D T Felson; M Dougados
Journal:  Arthritis Rheum       Date:  2001-08

6.  What is the most appropriate radiologic scoring method for ankylosing spondylitis? A comparison of the available methods based on the Outcome Measures in Rheumatology Clinical Trials filter.

Authors:  Astrid J B Wanders; Robert B M Landewé; Anneke Spoorenberg; Maxime Dougados; Sjef van der Linden; Herman Mielants; Hille van der Tempel; Désirée M F M van der Heijde
Journal:  Arthritis Rheum       Date:  2004-08

7.  The Bath Ankylosing Spondylitis Radiology Index (BASRI): a new, validated approach to disease assessment.

Authors:  K MacKay; C Mack; S Brophy; A Calin
Journal:  Arthritis Rheum       Date:  1998-12

8.  Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial.

Authors:  John C Davis; Désirée Van Der Heijde; Jurgen Braun; Maxime Dougados; John Cush; Daniel O Clegg; Alan Kivitz; Roy Fleischmann; Robert Inman; Wayne Tsuji
Journal:  Arthritis Rheum       Date:  2003-11

9.  Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis.

Authors:  J Brandt; A Khariouzov; J Listing; H Haibel; H Sörensen; L Grassnickel; M Rudwaleit; J Sieper; J Braun
Journal:  Arthritis Rheum       Date:  2003-06

10.  Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis.

Authors:  J Brandt; J Listing; J Sieper; M Rudwaleit; D van der Heijde; J Braun
Journal:  Ann Rheum Dis       Date:  2004-03-25       Impact factor: 19.103

View more
  3 in total

Review 1.  [Self-monitoring in inflammatory rheumatic diseases].

Authors:  C Kampling; G Chehab; M Schneider; J G Richter
Journal:  Z Rheumatol       Date:  2014-10       Impact factor: 1.372

Review 2.  [Spondyloarthritis and quality of life].

Authors:  J Hermann
Journal:  Z Rheumatol       Date:  2010-05       Impact factor: 1.372

Review 3.  [Measuring quality of life in rheumatic disease. A critical appraisal].

Authors:  T Meyer; H Raspe
Journal:  Z Rheumatol       Date:  2010-05       Impact factor: 1.372

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.